JP2006008527A - Obesity inhibition composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide foods and drinks, drugs or quasi drugs which excel in safety, do not increase a load even by daily intake and exhibits a higher obesity preventing or ameliorating action and are effective for obesity caused by life style by the action to inhibit the rise in blood sugar level to prevent or ameliorate diabetes, the action to prevent hyperlipemia and the like. <P>SOLUTION: An obesity inhibition composition comprises an enzyme treated product of Emblica officinale or Phyllanthus embilica, and the enzyme for treating Emblica officinale or Phyllanthus embilica is preferably one or more kinds selected from pectinase, cellulase, hemicellulase, protease, tannase, and chlorogenic acid esterase. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an obesity suppressing composition.

  In recent years, the proportion of obese (overweight) humans has increased with the westernization of eating habits. Obesity also causes diabetes, arteriosclerosis, etc., so the development of drugs and methods for its prevention and improvement has become a major issue both medically and socially. Obesity, diabetes, arteriosclerosis, and the like are recently called lifestyle-related diseases because their onset is greatly influenced by lifestyle factors such as diet and environmental factors in addition to genetic elements. Obesity is the result of a large amount of energy derived from overdose food being accumulated in fat cells as neutral lipids (triacylglycerol). Recently, for diet foods intended for slimming, products containing various compounds such as L-carnitine, capsaicin, conjugated linoleic acid, hydroxycitric acid, gymnema and garcinia have been developed. Although the mechanism of these actions has not been clarified sufficiently, activation of lipid metabolism, inhibition of sugar absorption, inhibition of lipid synthesis, and the like are considered. In addition, low-calorie food materials such as aspartame have been developed.

  In recent years, it has become clear that insulin resistance is observed in many pathological conditions such as diabetes, abnormal glucose metabolism, obesity, abnormal lipid metabolism, and hypertension, and its importance has been widely recognized. There are currently 6 million diabetics in the country, and it is estimated that there are almost twice as many reserves. Diabetes is broadly divided into insulin-dependent (IDDM) and non-insulin-dependent (NIDDM). Insulin-dependent insulin is induced by necrosis or dysfunction of pancreatic β-cells by autoimmune mechanisms caused by viruses. Can not be synthesized and secreted, accounting for almost 10% of patients. Insulin-independent type is a type that shows hyperglycemia due to insulin secretion failure and tissue insulin resistance caused by uncertain factors such as aging and stress, and more than 90% of patients are included in this type It is. Dietary therapy and exercise therapy are mainly used for treatment of patients with this type of mild or moderate disease, and stabilization of blood sugar level is achieved by limiting calorie restriction of the diet and promoting metabolism of sugar by exercise. However, if the blood glucose level suddenly rises and persists after meals (post-prandial hyperglycemia) for many years, vascular disorders are promoted with the worsening of diabetes, neurosis, nephropathy, retinopathy, and even myocardial infarction, There is a risk of complications such as stroke. Suppression of postprandial hyperglycemia is said to be effective in preventing the onset of non-insulin-dependent diabetes mellitus, and α-glucosidase inhibitors such as acarbose are marketed as ethical drugs, but from the viewpoint of preventing or preventing deterioration of diabetes Further enhancement of therapy is desired. In addition, stress is another factor that causes hyperglycemia other than diabetes. The present age is also called a stress society, and there are many people who feel stress from children to adults. In addition, there are many people who eat and drink from this stress. Stress is said to excite sympathetic nerves and promote the secretion of adrenaline and noradrenaline, which increases blood glucose levels. Therefore, there is a risk of becoming a hyperglycemic state if stress conditions in daily life, followed by excessive drinking and eating, etc., lead to the development of complications similar to diabetes, so blood sugar levels due to daily suppression of postprandial hyperglycemia etc. Control is needed.

  For example, in a natural product system, a blood glucose level lowering agent (for example, refer to Patent Document 1) containing a tea water-soluble polysaccharide component thealactone as an active ingredient (for example, see Patent Document 1), an antidiabetic agent containing a hot water extract fraction of banaba leaves (for example, Patent Document 2), xanthone hypoglycemic agent extracted and extracted from the assembly (for example, see Patent Document 3), insulin-like agent containing trans-10-hydroxydecenoic acid contained in royal jelly as an active ingredient ( For example, see Patent Document 4.). In addition, as a chemical synthesis product, a molanolin N-substituted derivative (for example, see Patent Document 5), a thiazolidine compound (for example, see Patent Document 6), and a condensed 7-membered ring system compound having an imidazolyl group (for example, Patent Document 7). See).

  However, excessive intake of ingredients having the effects described above may cause loose stool and diarrhea, inflammation of the intestinal mucosa, decreased immunity, and mental instability. It has been difficult to add a sufficient amount (effective amount) to foods due to flavor problems.

JP-A-4-124139 (page 1-8) JP-A-7-228539 (page 1-5) JP-A-7-206673 (pages 1-8) JP-A-9-67252 (page 1-4) Japanese Examined Patent Publication No. 59-43949 (Pages 1-15) Japanese Patent Laid-Open No. 4-210977 (page 1-13) JP-A-4-178811 (pages 1-24)

  It is an object of the present invention to have an excellent effect of suppressing the increase in serum glucose concentration and high fat, which is excellent in safety, does not become a burden on daily intake, and has a higher obesity prevention / amelioration action and also prevents / ameliorates diabetes. The present invention provides foods and beverages and pharmaceuticals that are effective against obesity caused by lifestyle habits such as an inhibitory effect on the increase in serum triglyceride concentration that prevents and improves blood glucose.

  As a result of diversified research and studies for the purpose of searching for functional foods that suppress obesity using various natural plants, the present inventors have demonstrated that obesity suppression is superior to enzyme-treated products obtained by amla enzyme treatment. As a result, the present invention has been completed.

The obesity-suppressing composition obtained in the present invention is based on the results of animal experiments with a high sucrose diet and a high cholesterol diet. From the results of animal experiments, suppression of body weight gain, suppression of serum glucose concentration increase, suppression of serum cholesterol concentration increase, and suppression of serum triglyceride concentration increase It turns out that an effect is high.
In particular, Amla is safe because it has no side effects that cause bleeding in the body, unlike conventional drugs because it is derived from a natural plant that humans have used for a long time.

  Amla used in the present invention is a scientific name: Emblica officinale or Philanthus embrica, which is a sub-tree of deciduous trees belonging to the genus Euphorbiaceae, from the Indian region to southern Malaysia It is distributed over the country, and India is considered the origin. In addition, each region or language has its own unique name, such as citrus, oil sweets, Satsuma mushrooms, Emblic Mirobaran, Armala Key, Melaka tree, Malacca tree, Indian Gooseberry, Aronra, Amira, Amiraki, Amira Cattra, Nerikai, It is also called Neruri, Tasha, Kayuraka, Kemuraka, Nakhon Pong and others.

  The country of origin of Amla used in the present invention is from India to the Malaysia region and southern China, and any of those cultivated in these regions can be used, but preferably from the viewpoint of medicinal plants, India Or it is cultivated in China, Most preferably, it is cultivated in India from the viewpoint of the medicinal plant prescribed by Ayurveda.

  In the present invention, the site of Amla is not particularly limited, but fruits, roots, stems, leaves, and flowers can be used. Preferably, a fruit can be used from the viewpoint of productivity. The form is not particularly limited, and any of immature fruits, fully-ripe fruits, dried fruits and the like may be used.

The enzyme used in the present invention is not particularly limited as long as it is used for the food industry. Pectinase, cellulase, hemicellulase, α-amylase, glucoamylase, maltotriohydrolase, β-amylase, transglucosidase, lipase, used protease, glutaminase, nuclease, deaminase, dextranase, glucose oxidase, lactase, tannase, chlorogenic acid esterase, pullulanase, trypsin, papain, rennet, selected from phospholipase a _2, etc., one or two or more enzymes be able to. Preferably, one or two or more enzymes selected from pectinase, cellulase, hemicellulase, protease, chlorogenic acid esterase, and tannase can be used.

  The amount of enzyme added when producing the obesity-suppressing composition of the present invention can be appropriately selected depending on the specific activity of the enzyme used, but is different between undried and dried Amla fruits. For example, (1) when the specific activity of pectinase used in an undried Amla fruit is 50000 U / mL in AJDA (Apple Juice Detecting Activity), it is 50 to 2000 ppm, preferably 100 to 1000 ppm with respect to Amla. Most preferably, it is 300-500 ppm. When the addition amount is less than 50 ppm, the treatment of Amla fruit tissue with pectinase becomes insufficient, and the production amount is small. Even if the addition amount exceeds 2000 ppm, the rate of the enzymatic reaction does not increase, and the production of the obesity-suppressing composition of the present invention Yield does not increase much. (2) When the Amla fruit is dry, and the specific activity of the pectinase used is EndoPGASE (Endopolygalacturonase) activity 1800 U / mL and CMCase (Carboxymethylcellulose) activity 50,000 U / mL, the combination of Amla fruit and solution part It is 50-2000 ppm, Preferably it is 100-1000 ppm, Most preferably, it is 300-500 ppm. When the addition amount is less than 50 ppm, the treatment of Amla fruit tissue with pectinase is insufficient and the production yield is low. Even if the addition amount exceeds 2000 ppm, the rate of enzyme reaction does not increase, and the obesity-suppressing composition of the present invention Production yield does not increase much.

  The treatment time when producing the obesity-suppressing composition of the present invention is not particularly limited, but differs between undried fruits and dried fruits. For example, (1) When Amla fruit is undried, the treatment time is 0.5 to 12 hours, preferably 2 to 8 hours, and most preferably 3 to 5 hours from the viewpoint of productivity. . When the treatment time is less than 0.5 hours, the treatment of Amla fruit tissue becomes insufficient, and the production yield of the obesity-suppressing composition of the present invention does not increase so much. (2) When Amla fruit is dried, from the viewpoint of productivity, the treatment time is 0.5 to 48 hours, preferably 2 to 24 hours, and most preferably 5 to 20 hours. When the treatment time is less than 0.5 hours, the treatment of Amla fruit tissue is insufficient, and the production yield of the obesity-suppressing composition of the present invention is small. Even if the treatment time exceeds 24 hours, the treatment of the Amla fruit part does not proceed any further, and the production yield of the obesity suppressing composition of the present invention does not increase so much.

  The obesity suppressing composition in the present invention is not particularly limited, and examples thereof include weight gain suppression, serum glucose concentration increase suppression, serum cholesterol concentration increase suppression, and serum triglyceride concentration increase suppression effect.

  The obesity-suppressing composition of the present invention can be applied to foods and drinks, pharmaceuticals, quasi drugs, feeds, etc., and preferably foods and drinks that can be easily consumed by humans.

  The food and drink in the present invention is not particularly limited as long as it is a form that can be taken orally, such as a solution, suspension, powder, or solid molded product. More specifically, instant noodles, retort food, canned food, microwave food, instant soups such as instant soup and miso soup, freeze-dried food, soft drink, fruit juice drink, vegetable drink, soy milk drink, coffee drink, tea drink Beverages such as powdered beverages, concentrated beverages, nutritional beverages, alcoholic beverages, bread, pasta, noodles, cake mixes, flour products such as fried flour and bread crumbs, rice cakes, caramel, chewing gum, chocolate, cookies, biscuits, cakes, Sweets such as pies, snacks, crackers, Japanese sweets, desserts, sauces, processed tomato seasonings, flavor seasonings, cooking mixes, sauces, dressings, soups, curry and stew seasonings, processing Fats and oils such as butter, margarine and mayonnaise, milk beverages, yogurts, lactic acid bacteria beverages, ice creams, chestnuts Agricultural processing of dairy products such as mussels, frozen foods, processed fishery products such as fish ham and sausages, marine products, processed livestock products such as livestock ham and sausages, canned agricultural products, jams and marmalades, pickles, boiled beans and cereals Agricultural products such as products, nutritional foods, and cereals. Examples of feed include dairy farming, pig farming, chicken farming, and fish farming. Examples of pharmaceuticals or quasi drugs include internal liquids, tablets, dragees, sublingual tablets, granules, capsules (hard capsules, soft capsules, microcapsules), liquids, emulsions, suspensions, powders, and the like. Illustrated.

In the present invention, the obesity-suppressing composition can enhance various nutritional components when processed into foods and drinks, feeds, and pharmaceuticals.
Nutritional ingredients that can be strengthened include vitamins such as vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin D, vitamin E, niacin (nicotinic acid), pantothenic acid, folic acid, Essential amino acids such as lysine, threonine and tryptophan, minerals such as calcium, magnesium, iron, zinc and copper, and for example, α-linolenic acid, EPA, DHA, evening primrose oil, octacosanol, casein phosphopeptide (CPP), Casein calcium peptide (CCP), water-soluble dietary fiber, insoluble dietary fiber, substances that contribute to human health, such as oligosaccharides, and one or more useful substances approved as other foods and food additives Can be used.

  EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, the following Example does not limit the scope of the present invention.

(Example 1) Preparation of obesity-suppressing composition 1
1 liter of distilled water and 0.1 g of pectinase A (manufactured by Amano Enzyme, derived from Aspergillus, 12000 U / mL) were added to 100 g of dried Amla fruits, and extracted at 55 ° C. for 2 hours. Thereafter, the enzyme was inactivated at 90 ° C. for 30 minutes. Then, it filtered and the filtrate was spray-dried and 55g of obesity suppression compositions of this invention were obtained.

(Test Example 1) Body weight measurement test SD rats (3 weeks old, male) were preliminarily bred for 1 week and divided into 2 groups of 5 animals each. Based on (cholesterol diet), the compounded feed shown in Table 2 was freely taken for 6 weeks, and changes in body weight were examined. The breeding was performed under conditions of a temperature of 23 ± 2 ° C., a humidity of 55 ° C. ± 5%, and illumination for 12 hours / day.

  The test results are shown in FIG. FIG. 1 shows the average value of body weight for each group after 6 weeks. As is clear from the figure, the amla enzyme group showed a high effect on weight gain suppression (p <0.05).

(Test Example 2) Blood glucose level measurement After the breeding of Test Example 1, blood was collected from the abdominal aorta under ether anesthesia, and serum glucose was measured. The result is shown in FIG. As is apparent from the graph, it was confirmed that the increase in serum glucose concentration was significantly suppressed in the Amla enzyme group obtained in Example 1 compared to the control group (p <0.05).

(Test Example 3) Triglyceride level and cholesterol level measurement test of serum After the breeding of Test Example 1, blood was collected from the abdominal aorta under ether anesthesia, and serum glyceride and serum cholesterol were measured. The results are shown in FIGS.
As is clear from FIG. 3, the Amla enzyme group obtained in Example 1 showed a significant effect of suppressing the increase in serum triglyceride concentration compared to the control group (p <0.05).
As is clear from FIG. 4, the amla enzyme group obtained in Example 1 had a significantly lower total cholesterol level than the control group (p <0.05).
As is clear from FIG. 5, the Amla enzyme group obtained in Example 1 showed a significant inhibitory effect on the increase in LDL cholesterol concentration compared to the control group (p <0.05).
From FIG. 6, the amla enzyme group did not obtain a significant difference with respect to the HDL cholesterol concentration as compared with the control group.

(Example 2) Tablet 150 g of Amla enzyme-treated product obtained in Example 1 was mixed with 150 g of lactose and 5 g of magnesium stearate, and tableted with a tableting machine to obtain a tablet.

(Example 3) Chocolate Using the Amla enzyme-treated product obtained in Example 1, chocolate was produced with the following composition.
(Blending ingredients) (Blending amount)
Cacaomas 15.4g
Sugar (sucrose) 40.0g
Whole milk powder 25.0g
Cocoa butter 20.0g
Amla enzyme treatment product 1.0g
Lecithin 0.5g
Fragrance 0.05g

(Example 4) Cookie Using the Amla enzyme-treated product obtained in Example 1, a cookie having the following composition was produced.
(Blending ingredients) (Blending amount)
Flour 100.0g
Shortening 20.0g
10.0 g butter
Sugar (sucrose) 30.0g
4.0g egg
0.3g of salt
Amla enzyme processed product 0.5g
Expansion agent 0.5g
Fragrance 0.2g

(Example 5) Candy Using the Amla enzyme-treated product obtained in Example 1, a candy having the following composition was produced.
(Blending ingredients) (Blending amount)
Sugar (sucrose) 50.0g
Minamata 50.0g
Amla enzyme processed product 0.5g
Citric acid 0.3g
Fragrance 0.2g
Appropriate amount of dye

(Example 6) Health drink A health drink having the following composition was produced using the amla enzyme-treated product obtained in Example 1.
(Blending ingredients) (Blending amount)
15.0g of honey
Citric acid 0.1g
dl-malic acid 0.1g
Amla enzyme treatment product 2.0g
D-sorbitol solution (70%) 10.0 g
Sodium benzoate 0.05g
Perfume Appropriate amount of purified water

(Example 7) Fruit juice beverage Using the Amla enzyme-treated product obtained in Example 1, a fruit juice beverage having the following composition was produced.
(Blending ingredients) (Blending amount)
Glucose liquid sugar 33.0g
Grapefruit juice 40.0g
Amla enzyme treated product 5.0g
Fragrance Appropriate amount Acidity agent Appropriate amount

  According to the present invention, since the Amla enzyme-treated product has an excellent obesity-suppressing effect, the obesity-suppressing composition of the present invention containing the treated product as an active ingredient is used for the suppression, improvement and prevention of weight gain, fat accumulation disease It is useful for suppressing, improving and preventing diseases such as hyperlipidemia, thrombus, arteriosclerosis and cholesterolemia.

  Amla enzyme-treated product used in the present invention is a naturally derived substance, which is highly safe and optimal for ingestion in daily life. Food, food additive, animal feed, animal feed additive, The contribution to the pharmaceutical industry is expected to be significant.

It is a graph which shows the body weight comparison of the rat in a test example. It is a graph which shows the glucose concentration in the rat serum in a test example. It is a graph which shows the triglyceride density | concentration in the rat serum in a test example. It is a graph which shows the total cholesterol concentration in the rat serum in a test example. It is a graph which shows the LDL cholesterol density | concentration in the rat serum in a test example. It is a graph which shows the HDL cholesterol density | concentration in the rat serum in a test example.

Claims (7)

An obesity-suppressing composition comprising an enzyme-treated product of Amla 2. The obesity-suppressing composition according to claim 1, wherein the enzyme for treating amla is one or more selected from pectinase, cellulase, hemicellulase, protease, tannase, and chlorogenic acid esterase. The obesity-suppressing composition according to claim 1 or 2, wherein the site of Amla is a fruit. The obesity suppressing effect is one or more selected from a body weight gain suppressing effect, a serum glucose concentration increase suppressing effect, a serum cholesterol concentration increase suppressing effect, and a serum triglyceride concentration increase suppressing effect. 3. The obesity suppressing composition according to any one of 3 Food / beverage products containing the obesity suppression composition in any one of Claims 1-4 A feed comprising the obesity-suppressing composition according to claim 1. A pharmaceutical comprising the obesity-suppressing composition according to any one of claims 1 to 4.

Images